Exploring the Validity of Valproic Acid Animal Model of Autism

被引：185
作者：
Mabunga, Darine Froy N. [1 ,2 ,3 ]
Gonzales, Edson Luck T. [1 ,2 ,3 ]
Kim, Ji-woon [1 ,2 ,3 ]
Kim, Ki Chan [1 ,2 ,3 ]
Shin, Chan Young [1 ,2 ,3 ,4 ]
机构：
[1] Konkuk Univ, Dept Neurosci, Sch Med, Seoul 05029, South Korea
[2] Konkuk Univ, Neurosci Res Ctr, SMART IABS, Seoul 05029, South Korea
[3] Konkuk Univ, KU Open Innovat Ctr, Seoul 05029, South Korea
[4] Konkuk Univ, Sch Med, Dept Pharmacol, Seoul 05029, South Korea
来源：
EXPERIMENTAL NEUROBIOLOGY | 2015年 / 24卷 / 04期
基金：
新加坡国家研究基金会;
关键词：
autism spectrum disorder; construct validity; face validity; predictive validity; animal model; social communication deficit; INCREASED OXIDATIVE STRESS; NEURAL-TUBE DEFECTS; SPECTRUM DISORDERS; PRENATAL EXPOSURE; ENVIRONMENTAL ENRICHMENT; REPETITIVE BEHAVIOR; SOCIAL-INTERACTION; THERAPEUTIC APPROACH; ADDITIONAL EVIDENCE; MENTAL-RETARDATION;
D O I：
10.5607/en.2015.24.4.285
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The valproic acid (VPA) animal model of autism spectrum disorder (ASD) is one of the most widely used animal model in the field. Like any other disease models, it can't model the totality of the features seen in autism. Then, is it valid to model autism? This model demonstrates many of the structural and behavioral features that can be observed in individuals with autism. These similarities enable the model to define relevant pathways of developmental dysregulation resulting from environmental manipulation. The uncovering of these complex pathways resulted to the growing pool of potential therapeutic candidates addressing the core symptoms of ASD. Here, we summarize the validity points of VPA that may or may not qualify it as a valid animal model of ASD.
引用
收藏
页码：285 / 300
页数：16
相关论文
共 134 条
[71]   The Autism Diagnostic Observation Schedule-Generic: A standard measure of social and communication deficits associated with the spectrum of autism [J].
Lord, C ;
Risi, S ;
Lambrecht, L ;
Cook, EH ;
Leventhal, BL ;
DiLavore, PC ;
Pickles, A ;
Rutter, M .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2000, 30 (03) :205-223
[72]   Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia [J].
Lubow, RE .
SCHIZOPHRENIA BULLETIN, 2005, 31 (01) :139-153
[73]   ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease [J].
Maher, Pamela ;
Dargusch, Richard ;
Bodai, Laszlo ;
Gerard, Paul E. ;
Purcell, Judith M. ;
Marsh, J. Lawrence .
HUMAN MOLECULAR GENETICS, 2011, 20 (02) :261-270
[74]   Characterizing sleep in children with autism spectrum disorders: A multidimensional approach [J].
Malow, Beth A. ;
Marzec, Mary L. ;
McGrew, Susan G. ;
Wang, Lily ;
Henderson, Lynnette M. ;
Stone, Wendy L. .
SLEEP, 2006, 29 (12) :1563-1571
[75]   Abnormal fear conditioning and amygdala processing in an animal model of autism [J].
Markram, Kamila ;
Rinaldi, Tania ;
La Mendola, Deborah ;
Sandi, Carmen ;
Markram, Henry .
NEUROPSYCHOPHARMACOLOGY, 2008, 33 (04) :901-912
[76]   Risperidone in children with autism and serious behavioral problems [J].
McCracken, JT ;
McGough, J ;
Shah, B ;
Cronin, P ;
Hong, D ;
Aman, MG ;
Arnold, E ;
Lindsay, R ;
Nash, P ;
Hollway, J ;
McDougle, CJ ;
Posey, D ;
Swiezy, N ;
Kohn, A ;
Scahill, L ;
Martin, A ;
Koenig, K ;
Volkmar, F ;
Carroll, D ;
Lancor, A ;
Tierney, E ;
Ghuman, J ;
Gonzalez, NM ;
Grados, M ;
Vitiello, B ;
Ritz, L ;
Davies, M ;
Robinson, J ;
McMahon, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (05) :314-321
[77]   Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology [J].
McDougle, CJ ;
Hollway, J ;
Scahill, L ;
Koenig, K ;
Aman, MG ;
McGough, JJ ;
McCracken, JT ;
Ritz, L ;
Tierney, E ;
Vitiello, B ;
Davies, M ;
Arnold, LE ;
Posey, DJ ;
Martin, A ;
Ghuman, JK ;
Shah, B ;
Chuang, SZ ;
Swiezy, NB ;
Gonzalez, NM .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (06) :1142-1148
[78]   Further studies in the developmental hyperserotonemia model (DHS) of autism: Social, behavioral and peptide changes [J].
McNamara, Ilan M. ;
Borella, Alice W. ;
Bialowas, Lynn A. ;
Whitaker-Azmitia, Patricia M. .
BRAIN RESEARCH, 2008, 1189 :203-214
[79]   mGluR5-Antagonist Mediated Reversal of Elevated Stereotyped, Repetitive Behaviors in the VPA Model of Autism [J].
Mehta, Mili V. ;
Gandal, Michael J. ;
Siegel, Steven J. .
PLOS ONE, 2011, 6 (10)
[80]   Clinically Relevant Single Gene or Intragenic Deletions Encompassing Critical Neurodevelopmental Genes in Patients With Developmental Delay, Mental Retardation, and/or Autism Spectrum Disorders [J].
Mikhail, Fady M. ;
Lose, Edward J. ;
Robin, Nathaniel H. ;
Descartes, Maria D. ;
Rutledge, Katherine D. ;
Rutledge, S. Lane ;
Korf, Bruce R. ;
Carroll, Andrew J. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2011, 155A (10) :2386-2396
3456789101112